Jump to content

Metastatic castration-resistant prostate cancer remains andr


Recommended Posts

Metastatic castration-resistant prostate cancer remains androgen-driven 06/05/2011


The success of the recent trials with Zytiga don't just give hope in themselves.

They do show what many have suspected, but has not been proven until now:

"metastatic castration-resistant prostate cancer remains androgen-driven"

If you missed the latest report:

"active treatment [jm] was found to reduce the risk of death by 35%, compared with placebo. Mortality was 42% with active treatment, compared with 55% with placebo. Median overall survival was 14.8 months with abiraterone, compared with 10.9 months with placebo"

I am not a doctor.

Find the original article by searching Google for

abiraterone "may 26" new england journal of medicine

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...